PharmAthene News
Most Popular PharmAthene Story
PharmAthene bids for big anthrax vaccine contract
PharmAthene is making a bid to develop a next-gen anthrax vaccine that can qualify for a $400 million government contract. The small Maryland developer is paying up to $40 million for a pair of... Read more...
Latest Headlines
- October 2, 2008
- March 27, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
